Here's a very timely example from Saturday at the ACC 2017 meeting that is pertinent to my previous post, though I doubt it will affect Resverlogix share price much. Thanks to JK on the Stockhouse board for first posting on this.
Study Shows No Reduction of Plaque With Synthetic HDL-C Injection